Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
7,845 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07381764 | ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"(ROMANCE - GOIM) | recruiting | Phase 2 | 150 | Gruppo Oncologico Italia MeridionaleOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07546578 | Setting Up ctDNA Analysis on Archived Plasma Samples(DARE-part1) | recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma(CEVOLUTION) | recruiting | Phase 3 | 380 | Hoffmann-La RocheINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma(FOCUS) | completed | Phase 3 | 102 | Delcath Systems Inc.INDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT02910583 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)(Captivate) | completed | Phase 2 | 323 | Pharmacyclics LLC.INDUSTRY | 6 | Sep 10, 2026 | clinicaltrials |
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma(STRASS2) | recruiting | Phase 3 | 250 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Sep 10, 2026 | clinicaltrials |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 | clinicaltrials |
| NCT04471987 | Safety and Early Signs of Efficacy of IL12-L19L19.(DODEKA) | recruiting | Phase 1 | 80 | Philogen S.p.A.INDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT04931342 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors(BOUQUET) | active not recruiting | Phase 2 | 176 | Hoffmann-La RocheINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT05196269 | Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.(CINDERELLA) | active not recruiting | N/A | 1,030 | Fundacao ChampalimaudOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT05445843 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.(KontRASt-06) | active not recruiting | Phase 2 | 95 | Novartis PharmaceuticalsINDUSTRY | 19 | Sep 10, 2026 | clinicaltrials |
| NCT05552469 | Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases | active not recruiting | Phase 1 | 71 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT05852691 | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 83 | Hoffmann-La RocheINDUSTRY | 16 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT06809322 | Vorasidenib Maintenance for IDH Mutant Astrocytoma(VIGOR) | recruiting | Phase 3 | 468 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 10, 2026 | clinicaltrials |
| NCT06914128 | A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | recruiting | Phase 1 / Phase 2 | 450 | BayerINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT07335497 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors(ASCEND) | recruiting | Phase 1 / Phase 2 | 290 | Crescent Biopharma, Inc.INDUSTRY | 8 | Sep 10, 2026 | clinicaltrials |
| NCT07537569 | Preoperative Oncogeriatric Assessment in Patients Undergoing Hepatectomy | recruiting | N/A | 242 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07691255 | MELanoma Brain Metastasis Treated With CYberknife(MELCY) | recruiting | — | 50 | European Institute of OncologyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07691281 | Disparities in Mental Health Screening and Support(ALTHEA) | recruiting | — | 2,000 | European Institute of OncologyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01827605 | A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) | completed | Phase 3 | 159 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | active not recruiting | Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 429 | GenmabINDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT04124497 | A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients(DPd) | active not recruiting | Phase 2 | 45 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoADAURA) | active not recruiting | Phase 3 | 358 | AstraZenecaINDUSTRY | 25 | Sep 9, 2026 | clinicaltrials |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer(INTERLINK-1) | active not recruiting | Phase 3 | 370 | AstraZenecaINDUSTRY | 23 | Sep 9, 2026 | clinicaltrials |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome(EPCORE™ CLL-1) | active not recruiting | Phase 1 / Phase 2 | 194 | GenmabINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)(EPCORE™ NHL-2) | active not recruiting | Phase 1 / Phase 2 | 543 | GenmabINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT04915248 | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.(FIL_DALYA) | recruiting | Phase 2 | 28 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)(MY MYELOMA) | recruiting | — | 1,900 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer(IMforte) | active not recruiting | Phase 3 | 660 | Hoffmann-La RocheINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | active not recruiting | Phase 1 | 184 | AmgenINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer(ELECTRA) | recruiting | Phase 1 / Phase 2 | 73 | Stemline Therapeutics, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT05925530 | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)(MDT-BRIDGE) | active not recruiting | Phase 2 | 142 | AstraZenecaINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06578559 | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC(BRICKET) | active not recruiting | Phase 2 | 16 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | active not recruiting | Phase 3 | 191 | GenmabINDUSTRY | 27 | Sep 9, 2026 | clinicaltrials |
| NCT06854653 | A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | recruiting | Phase 2 | 115 | Prescient Therapeutics, Ltd.INDUSTRY | 4 | Sep 9, 2026 | clinicaltrials |
| NCT06897644 | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.(PANThEON) | recruiting | Phase 3 | 340 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 74 | PfizerINDUSTRY | 9 | Sep 9, 2026 | clinicaltrials |
| NCT06980480 | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma | recruiting | Phase 3 | 183 | TakedaINDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
Data updated 20 days agoSource updated unknownsource: clinicaltrials